Electronic IFUs (eIFUs): Multilingual Translation and Version Control

Depending on the device, jurisdiction, intended user, and approved delivery model, an eIFU may be:

• displayed by the medical device;
• embedded in device software;
• included in a mobile, desktop, or web application;
• supplied on electronic storage media;
• published as a downloadable PDF;
• delivered through a dedicated e-labeling portal; or
• accessed through a stable URL, QR code, or product-support page.

Under the current EU framework, an eIFU remains complete textual information; symbols and graphics may be included, while video or audio may supplement rather than replace the required text. Electronic delivery does not reduce the need for content control. It introduces additional objects that must remain connected throughout the device lifecycle.

A multilingual eIFU program succeeds when every target edition can be traced to the correct device, market, source revision, approved language, delivery format, and publication state.

Consider an IFU that supports four related device models, 18 European markets, 14 language editions, a downloadable PDF, device-integrated help, a paper-on-request file, and one archived prior revision. That program is not simply a set of 14 translations. It is a network of product, language, market, revision, channel, and status relationships.

One Source Change Can Create Unequal Language Impact

A revision may require different actions in different languages and markets:

• a new translation in every affected language;
• a terminology decision in only selected locales;
• layout reflow where translated text expands;
• right-to-left interface changes for Arabic;
• new screenshots for localized software;
• an updated paper file in markets where paper remains necessary; or
• no change where the affected device configuration is unavailable.

Digital and Paper Releases Can Drift Apart

The website may receive a new PDF before the print file is approved. A regional team may continue using a locally saved obsolete edition. Software help can be updated in one release while the downloadable manual remains unchanged. The solution is not merely better naming; it is a controlled release process that treats all formats as manifestations of the same approved information.

Electronic IFUs in the European Union

Commission Implementing Regulation (EU) 2021/2226, as amended by Regulation (EU) 2025/1234, establishes conditions for supplying electronic IFUs under the EU Medical Device Regulation. The 2025 amendment broadened eligibility for covered devices intended for professional users while retaining paper instructions for lay users where lay use is reasonably foreseeable.

A documented eIFU risk assessment may need to consider:

• intended-user knowledge and experience;
• the use environment;
• access to required hardware, software, and internet resources;
• protection against content tampering;
• backup mechanisms and temporary service unavailability;
• emergency situations;
• website compatibility;
• paper-copy fulfillment; and
• management of different IFU versions.

International Labeling Principles

The International Medical Device Regulators Forum’s 2024 labeling principles cover paper and electronic labeling while recognizing that individual authorities may impose additional requirements. A global eIFU program should distinguish the organization’s global content standard from product-specific, jurisdictional, language, and manufacturer-defined risk controls.

United States Quality-System Considerations

The FDA Quality Management System Regulation became effective on February 2, 2026 and incorporates ISO 13485:2016 by reference. Current 21 CFR 820.45 includes controls for labeling accuracy, documented release, and prevention of labeling and packaging mix-ups. FDA guidance also permits paper or electronic user manuals for specifically covered electronic products, but that guidance should not be generalized to every medical device. Electronic-delivery permissions remain product- and regulation-specific and should not be treated as a universal equivalent of the EU eIFU framework.

Content and Delivery Are Different Control Layers

ISO 20417:2026 addresses information supplied by medical device manufacturers but does not prescribe one universal delivery medium. Manufacturer-supplied information requirements and delivery-channel requirements are related, but they are not interchangeable. A valid digital channel does not correct incomplete content, and approved content can still fail when it is published under the wrong device, language, revision, or access path.

The source may reside in a controlled document management system, component content management system, XML or DITA repository, product lifecycle management environment, validated labeling platform, approved technical-publications workflow, or another governed system. The technology matters less than the controls around it.

Minimum Source-Control Information

• a unique document identifier and unambiguous revision;
• approval status, approval date, and effective date;
• identified product and intended-user scope;
• a documented content owner and change history;
• approved editable source files;
• controlled graphics and screenshots; and
• links to applicable terminology and reference materials.

Control Reusable Content at the Component Level

Reusing approved warnings, procedures, and maintenance instructions can reduce inconsistent updates. Reuse should still be confirmed for meaning, device context, intended user, market, related graphics, cross-references, and language approval.

The matrix should be controlled data, not a manually recreated spreadsheet attached to each release. Where spreadsheets are used, access, ownership, approval, and version history should be defined.

A complete change package should include:

• the newly approved source and prior approved source;
• a reliable redline or structured comparison;
• the change rationale and affected products or markets;
• safety or regulatory significance;
• the required release date;
• approved terminology changes;
• updated images, UI references, or software builds; and
• instructions for handling unchanged content.

Do Not Translate a Redline in Isolation

A changed sentence may depend on a warning immediately above it, a defined term introduced earlier, a numbered illustration, localized UI text, or a procedural sequence spread across several pages. Review the changed content in the complete IFU.

Distinguish Content Change From Format Change

A new source file may contain no meaningful linguistic change. A small source edit may require substantial target-language work. Separate semantic, terminology, numerical, identifier, layout, cross-reference, image, software-interface, metadata, and publication changes before assigning the localization scope.

Prepare a Complete Localization Package

Provide the language team with:

• the approved source revision and marked comparison;
• product, intended-use, language, and market context;
• approved terminology and previous approved translations;
• reference graphics, screenshots, and software context;
• style, formatting, and restricted-terminology requirements; and
• the required review and approval pathway.

For broader planning, see the Medical Device IFU Translation Guide.

Use Translation Memory as Controlled Evidence, Not Automatic Approval

Translation Memory can identify content that has already been translated and approved. A previous translation should still be reconsidered when the device context, intended user, market, language variant, neighboring content, warning sequence, or quality history has changed. A 100% text match is not always a 100% context match.

Maintain Medical Device Terminology Centrally

A governed Terminology Management program should record source terms, approved translations, definitions, context, product and market applicability, preferred and prohibited terms, abbreviations, approval status, and change history.

Apply Risk-Appropriate Human Review

Review depth should reflect content risk, intended audience, regulatory significance, novelty, product complexity, language complexity, software or layout dependency, and prior quality history. Back translation may be appropriate when required by a defined process or risk decision, but it should not automatically replace direct expert review.

Validate the Complete Deliverable

Final review should cover:

• linguistic accuracy and medical technical terminology;
• warnings, precautions, numbers, values, and units;
• product identifiers, image callouts, tables, and cross-references;
• bookmarks, navigation, URLs, QR destinations, and metadata;
• fonts, text expansion, right-to-left presentation, and accessibility; and
• comparison with the approved source.

Multilingual Desktop Publishing should be integrated with linguistic and technical QA rather than treated as a purely cosmetic final step.

Under the current EU framework, an electronic IFU supplied in addition to a complete paper IFU must remain consistent with the paper content. The same operational principle is useful more broadly: each delivery format should be generated from one approved content state.

Recommended Synchronization Rules

1. Use the same approved baseline. Do not maintain independent digital and print masters.
2. Generate outputs through controlled production paths. Avoid manually recreating content in each channel.
3. Apply one release decision. Record every applicable channel and language.
4. Verify packaging and access instructions. Test printed URLs, QR codes, software links, and paper-request instructions.
5. Control paper-on-request production. Print from an approved repository rather than local folders or email attachments.
6. Record fulfillment where required. Preserve the requested language, device, edition, dates, and delivery method.
7. Retire superseded print files. A new electronic release should trigger review of every paper-production repository.

Manage Page Numbers and References Carefully

Translation can change pagination. Section-based references, controlled heading identifiers, dynamically generated links, language-specific tables of contents, automated bookmarks, and final cross-reference validation are generally more robust than hard-coded page references.

Make Product Identification Unambiguous

Users should be able to locate the correct IFU through suitable identifiers such as:

• device name, product family, and model;
• catalog number and software version;
• Basic UDI-DI or UDI-DI, where applicable;
• market and language; and
• document number, revision, date, and current or archived status.

Use Clear Language and Locale Labels

Use language names and locale distinctions where necessary, such as French—France, French—Canada, Portuguese—Brazil, Portuguese—Portugal, Chinese—Simplified, and Chinese—Traditional. Flags alone should not be used as language labels.

Test Stable Access and File Integrity

Operational testing should include:

• direct links, redirects, QR codes, and download behavior;
• browser compatibility, mobile presentation, and language-selector behavior;
• search results, authentication barriers, and error pages;
• content-delivery caching, backup, and recovery procedures; and
• protection against unauthorized content changes.

Validate Software-Integrated Instructions

Confirm that:

• the correct language package loads;
• the eIFU matches the software and device version;
• navigation labels match the localized interface;
• embedded links open the correct language edition;
• text is not truncated and warnings remain prominent;
• keyboard, touch, and right-to-left behavior remain usable; and
• offline or backup access behaves as intended.

Use the Medical Device Software Localization Checklist for a deeper software-focused validation workflow.

Control Archived Editions

Archived eIFUs should remain retrievable where required without appearing to be the current edition. Use a visible archived or superseded label, provide a route to the current edition, preserve publication dates, protect file integrity, apply documented retention rules, and prevent accidental overwriting.

Productive Uses of AI and Automation

• compare source revisions and identify changed segments;
• classify possible change impact for human confirmation;
• detect terminology candidates and inconsistent usage;
• pretranslate suitable new content;
• flag numbers, units, product names, and missing translations;
• compare warnings across languages;
• find broken links and incorrect metadata; and
• route higher-risk content to specialist review.

Keep Accountable Human Judgment Where It Matters Most

Professional human review remains particularly important for intended use, indications, contraindications, warnings, emergency instructions, procedural steps, clinical or performance statements, nuanced risk communication, and market-specific regulatory language. Fluency is not approval.

Establish AI Governance

Define approved tools, data-handling requirements, confidentiality controls, permitted content categories, human-review thresholds, audit-log expectations, terminology sources, output-retention rules, exception handling, and final approval authority. Automation should accelerate a controlled process, not create a parallel one.

A responsibility model should identify who may:

• approve the source and determine market applicability;
• classify a change and approve terminology;
• approve each language edition;
• release a digital file or software-integrated edition;
• authorize a safety notification;
• retire an obsolete version; and
• provide an archived or paper copy.

Separate Preparation From Approval

The person publishing a file should not have to infer whether it is approved. A release package should state what is being released, for which product, in which market and language, through which channel, under which revision, on which date, and with whose approval.